JOHNSON & JOHNSON (JNJ)
JOHNSON & JOHNSON (JNJ) from its SEC filings: 2025 revenue $94.2 billion (+6% vs the year before), net margin 28%, free cash flow $19.7 billion. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $94.2 billion |
| Revenue growth | +6% |
| Net income | $26.8 billion |
| Net margin | 28.5% |
| Free cash flow | $19.7 billion |
| Diluted EPS | $11.03 |
| Latest quarter (Q3 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $16.9 billion |
| Long-term debt | $35.8 billion |
| Share count, 1 year | -0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.